ArticleInvestigational new drugs2026
Clinical features, treatment and outcomes of pembrolizumab induced autoimmune hemolytic anemia.
Article in Investigational new drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review of machine learning approaches for predicting sickle cell crisis and mortality risk at the climate-health nexus.BMC medical informatics and decision making · 2026Pooled it
- Molecular Genetics ofEcology and evolution · 2026Article
- CircHIPK3 promotes the progression of B-cell acute lymphoblastic leukemia in children by binding to STAT3.Frontiers in pharmacology · 2026Article
- Early-Onset Direct Antiglobulin Test-Negative Autoimmune Hemolytic Anemia Induced by Pembrolizumab in Perioperative Triple-Negative Breast Cancer: A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
To explore the clinical characteristics of pembrolizumab induced autoimmune hemolytic anemia (AIHA) and to provide references for diagnosis, treatment and prognosis. Case reports and case series of pembrolizumab induced AIHA were collected by searching the database and the clinical data of patients were summarized for statistical analysis up to August 31, 2025. Sixteen cases (55.2%) of male patients and 13 cases (44.8%) of female patients were included, with a median age of 69 years (36,85). The median time to develop AIHA after the first administration was 30 days (range 10,780), and the median cycle was 2.5 cycles (range 1,33). Clinical symptoms can be manifested as fatigue (13.8%), shortness of breath (10.3%), dyspnea (10.3%) and dizziness (6.9%). Direct antiglobulin test showed negative results (17.2%). Warm AIHA accounted for 44.8% of pembrolizumab induced AIHA. Peripheral blood smear examination showed spherocytes (20.7%), red cell agglutination (10.3%). After discontinuation of pembrolizumab and treatment with glucocorticoids (100%) and red blood cell infusion (69.0%), 96.5% of the patients achieved a treatment response. AIHA is a rare and serious complication of pembrolizumab. Clinicians should be aware of the possibility of AIHA occurrence during the treatment process. DAT negativity does not rule out pembrolizumab -induced AIHA. Glucocorticoids may be an important option for the treatment of AIHA. For refractory AIHA, second-line treatment needs to be initiated.
Indexed as
Identifiers
41511614What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.